Common examples of targeted therapies are the use of BRAF V600E inhibitors in melanoma patients, imatinib to target BCR‐ABL translocations in chronic myeloid leukaemia and PD1/PD‐L1 inhibitors for the immunotherapeutic treatment of melanoma, lung, renal and other cancer types. This evidence concerns the gene BRAF and melanoma.